{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:40:28Z","timestamp":1793731228517,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,3,18]],"date-time":"2011-03-18T00:00:00Z","timestamp":1300406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s11095-011-0405-x","type":"journal-article","created":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T19:42:46Z","timestamp":1300390966000},"page":"1696-1706","source":"Crossref","is-referenced-by-count":45,"title":["Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species"],"prefix":"10.1007","volume":"28","author":[{"given":"Yulia","family":"Vugmeyster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Szklut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wensel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Awwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lioudmila","family":"Tchistiakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garvin","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,18]]},"reference":[{"key":"405_CR1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916\u20139.","journal-title":"Nat Med"},{"key":"405_CR2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1749-6632.2000.tb06936.x","volume":"920","author":"D Games","year":"2000","unstructured":"Games D, Bard F, Grajeda H, Guido T, Khan K, Soriano F, et al. Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1\u201342. Ann N Y Acad Sci. 2000;920:274\u201384.","journal-title":"Ann N Y Acad Sci"},{"key":"405_CR3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/rej.2006.9.77","volume":"9","author":"CA Lemere","year":"2006","unstructured":"Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 2006;9:77\u201384.","journal-title":"Rejuvenation Res"},{"key":"405_CR4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1517\/14712590902828285","volume":"9","author":"GA Jicha","year":"2009","unstructured":"Jicha GA. Is passive immunization for Alzheimer\u2019s disease \u2018alive and well\u2019 or \u2018dead and buried\u2019? Expert Opin Biol Ther. 2009;9:481\u201391.","journal-title":"Expert Opin Biol Ther"},{"key":"405_CR5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-2008-15404","volume":"15","author":"DM Wilcockand","year":"2008","unstructured":"Wilcockand DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer\u2019s disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis. 2008;15:555\u201369.","journal-title":"J Alzheimers Dis"},{"key":"405_CR6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nm0198-097","volume":"4","author":"L Holcomb","year":"1998","unstructured":"Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97\u2013100.","journal-title":"Nat Med"},{"key":"405_CR7","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1523\/JNEUROSCI.17-18-07053.1997","volume":"17","author":"MC Irizarry","year":"1997","unstructured":"Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 1997;17:7053\u20139.","journal-title":"J Neurosci"},{"key":"405_CR8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","volume":"21","author":"T Kawarabayashi","year":"2001","unstructured":"Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer\u2019s disease. J Neurosci. 2001;21:372\u201381.","journal-title":"J Neurosci"},{"key":"405_CR9","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1073\/pnas.0600948103","volume":"103","author":"JS Jacobsen","year":"2006","unstructured":"Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2006;103:5161\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"405_CR10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/187152709787601830","volume":"8","author":"TE Golde","year":"2009","unstructured":"Golde TE, Das P, Levites Y. Quantitative and mechanistic studies of abeta immunotherapy. CNS Neurol Disord Drug Targets. 2009;8:31\u201349.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"405_CR11","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1096\/fj.06-6463fje","volume":"20","author":"Y Levites","year":"2006","unstructured":"Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer\u2019s disease mouse models. Faseb J. 2006;20:2576\u20138.","journal-title":"Faseb J"},{"key":"405_CR12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1474-4422(03)00349-1","volume":"2","author":"RC Dodel","year":"2003","unstructured":"Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer\u2019s disease. Lancet Neurol. 2003;2:215\u201320.","journal-title":"Lancet Neurol"},{"key":"405_CR13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","volume":"31","author":"DL Brody","year":"2008","unstructured":"Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008;31:175\u201393.","journal-title":"Annu Rev Neurosci"},{"key":"405_CR14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.febslet.2005.01.002","volume":"579","author":"MN Gaugler","year":"2005","unstructured":"Gaugler MN, Tracy J, Kuhnle K, Crameri A, Nitsch RM, Mohajeri MH. Modulation of Alzheimer\u2019s pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo. FEBS Lett. 2005;579:753\u20136.","journal-title":"FEBS Lett"},{"key":"405_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11481-008-9114-6","volume":"3","author":"RA Karlnoski","year":"2008","unstructured":"Karlnoski RA, Rosenthal A, Alamed J, Ronan V, Gordon MN, Gottschall PE, et al. Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice. J Neuroimmune Pharmacol. 2008;3:187\u201397.","journal-title":"J Neuroimmune Pharmacol"},{"key":"405_CR16","doi-asserted-by":"crossref","unstructured":"Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X. Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. J Pharm Sci. 99:1028\u201345.","DOI":"10.1002\/jps.21855"},{"key":"405_CR17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0031-9384(01)00524-8","volume":"73","author":"C Janus","year":"2001","unstructured":"Janus C, Westaway D. Transgenic mouse models of Alzheimer\u2019s disease. Physiol Behav. 2001;73:873\u201386.","journal-title":"Physiol Behav"},{"key":"405_CR18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1471-4159.2007.05064.x","volume":"104","author":"P Lichtlen","year":"2008","unstructured":"Lichtlen P, Mohajeri MH. Antibody-based approaches in Alzheimer\u2019s research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem. 2008;104:859\u201374.","journal-title":"J Neurochem"},{"key":"405_CR19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1006\/phrs.2000.0670","volume":"42","author":"P Yu","year":"2000","unstructured":"Yu P, Oberto G. Alzheimer\u2019s disease: transgenic mouse models and drug assessment. Pharmacol Res. 2000;42:107\u201314.","journal-title":"Pharmacol Res"},{"key":"405_CR20","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0090-9556(25)07501-4","volume":"24","author":"CB Davis","year":"1996","unstructured":"Davis CB, Garver EM, Kwok DC, Urbanski JJ. Disposition of metabolically radiolabeled CE9.1\u2013a macaque-human chimeric anti-human CD4 monoclonal antibody\u2013in transgenic mice bearing human CD4. Drug metabolism and disposition: the biological fate of chemicals. 1996;24:1032\u20137.","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"405_CR21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1208\/s12248-008-9045-4","volume":"10","author":"WS Putnam","year":"2008","unstructured":"Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. The AAPS Journal. 2008;10:425\u201330.","journal-title":"The AAPS Journal"},{"key":"405_CR22","doi-asserted-by":"crossref","first-page":"45897","DOI":"10.1074\/jbc.M407668200","volume":"279","author":"J Ghiso","year":"2004","unstructured":"Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, et al. Systemic catabolism of Alzheimer\u2019s Abeta40 and Abeta42. J Biol Chem. 2004;279:45897\u2013908.","journal-title":"J Biol Chem"},{"key":"405_CR23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1055\/s-0038-1654837","volume":"11","author":"A Amris","year":"1964","unstructured":"Amris A, Amris CJ. Turnover and distribution of 131-iodine-labelled human fibrinogen. Thromb Diath Haemorrh. 1964;11:404\u201322.","journal-title":"Thromb Diath Haemorrh"},{"key":"405_CR24","first-page":"455","volume":"2","author":"S Areekul","year":"1971","unstructured":"Areekul S, Devakul K, Chongsuphajaisiddhi T, Vivatanasesth P, Kanakakorn K, Kasemsuth R. Metabolism of 131 I-labelled fibrinogen in monkeys infected with Plasmodium coatneyi. Southeast Asian J Trop Med Public Health. 1971;2:455\u201361.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"405_CR25","first-page":"609","volume":"76","author":"AK Moza","year":"1982","unstructured":"Moza AK, Sapru RP. Turnover of radio-iodinated and biosynthetically labelled fibrinogen in rhesus monkeys. Indian J Med Res. 1982;76:609\u201317.","journal-title":"Indian J Med Res"},{"key":"405_CR26","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1538-7836.2008.03076.x","volume":"6","author":"C Negrier","year":"2008","unstructured":"Negrier C, Rothschild C, Goudemand J, Borg JY, Claeyssens S, Alessi MC, et al. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. J Thromb Haemost. 2008;6:1494\u20139.","journal-title":"J Thromb Haemost"},{"key":"405_CR27","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1172\/JCI106658","volume":"50","author":"GN Tytgat","year":"1971","unstructured":"Tytgat GN, Collen D, Verstraete M. Metabolism of fibrinogen in cirrhosis of the liver. J Clin Invest. 1971;50:1690\u2013701.","journal-title":"J Clin Invest"},{"key":"405_CR28","doi-asserted-by":"crossref","unstructured":"Bonfanti U, Lamparelli D, Colombo P, Bernardi C. Hematology and serum chemistry parameters in juvenile cynomolgus monkeys (Macaca fascicularis) of Mauritius origin: comparison between purpose-bred and captured animals. J Med Primatol. 2009.","DOI":"10.1111\/j.1600-0684.2009.00345.x"},{"key":"405_CR29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0014-5793(90)80760-G","volume":"264","author":"RA Stern","year":"1990","unstructured":"Stern RA, Trojanowski JQ, Lee VM. Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood. FEBS Lett. 1990;264:43\u20137.","journal-title":"FEBS Lett"},{"key":"405_CR30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/00001721-199609000-00011","volume":"7","author":"DL Merkle","year":"1996","unstructured":"Merkle DL, Cheng CH, Castellino FJ, Chibber BA. Modulation of fibrin assembly and polymerization by the beta-amyloid of Alzheimer\u2019s disease. Blood Coagul Fibrinolysis. 1996;7:650\u20138.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"405_CR31","doi-asserted-by":"crossref","unstructured":"Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D et al. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer\u2019s disease. Neuron. 66:695\u2013709.","DOI":"10.1016\/j.neuron.2010.05.014"},{"issue":"Pt 3","key":"405_CR32","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1042\/bj2881053","volume":"288","author":"J Ghiso","year":"1992","unstructured":"Ghiso J, Rostagno A, Gardella JE, Liem L, Gorevic PD, Frangione B. A 109-amino-acid C-terminal fragment of Alzheimer\u2019s-disease amyloid precursor protein contains a sequence, -RHDS-, that promotes cell adhesion. Biochem J. 1992;288(Pt 3):1053\u20139.","journal-title":"Biochem J"},{"key":"405_CR33","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1083\/jcb.200801146","volume":"182","author":"TA Springer","year":"2008","unstructured":"Springer TA, Zhu J, Xiao T. Structural basis for distinctive recognition of fibrinogen gamma C peptide by the platelet integrin alphaIIbbeta3. J Cell Biol. 2008;182:791\u2013800.","journal-title":"J Cell Biol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-011-0405-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-011-0405-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-011-0405-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T16:00:53Z","timestamp":1741104053000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-011-0405-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,18]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1007\/s11095-011-0405-x","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,18]]}}}